The relationship between chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) is important, significant and overlapping in nature. This review will analyze the relationship ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

“Oftentimes, most patients have both emphysema and chronic bronchitis, which is why we often just refer to it as COPD,” Dr. Beuther adds. About 3 out of 4 cases of COPD are caused by smokin ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

With proper management, most allergic bronchitis patients achieve good symptom control and prevent progression to chronic conditions. Early recognition of warning signs, prompt treatment ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...